More Favorable Metabolic Impact of Three-Times-Weekly Versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children

Overview

Journal Int J Endocrinol

Publisher Wiley

Specialty Endocrinology

Date 2017 Jun 22

PMID 28634491

Citations 3

Authors

Alessandro Ciresi

Floriana Ciccio

Stefano Radellini

Valentina Guarnotta

Anna Maria Calcaterra

Carla Giordano

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate whether two different regimens of weekly injections could lead to similar auxological and metabolic effects in children with growth hormone deficiency (GHD).

Design: 32 GHD children (25 males, mean age 10.5 ± 2.2 yr) were randomly assigned to receive daily (group A, 16 patients) or TIW (group B, 16 patients) GHT for 12 months.

Methods: Auxological parameters, insulin-like growth factor-I (IGF-I), glucose and insulin during OGTT, glycosylated hemoglobin (HbA1c), lipid profile, the oral disposition index (DIo), the homeostasis model assessment estimate of insulin resistance (Homa-IR), and the insulin sensitivity index (ISI).

Results: After 12 months, both groups showed a significant and comparable improvement in height ( < 0.001) and IGF-I ( < 0.001). As regards the metabolic parameters, in both groups, we found a significant increase in fasting insulin ( < 0.001 and = 0.026) and Homa-IR ( < 0.001 and = 0.019). A significant increase in fasting glucose ( = 0.001) and a decrease in ISI ( < 0.001) and DIo ( = 0.002) were only found in group A.

Conclusions: The TIW regimen is effective and comparable with the daily regimen in improving auxological parameters and has a more favorable metabolic impact in GHD children. This trial is registered with ClinicalTrials.gov NCT03033121.

Citing Articles

Yearly Height Gain Is Dependent on the Truly Received Dose of Growth Hormone and the Duration of Periods of Poor Adherence: Practical Lessons From the French Easypod™ Connect Multicenter Observational Study.

Coutant R, Nicolino M, Cammas B, de Buyst V, Tauber M, Hamel J Front Endocrinol (Lausanne). 2022; 12:790169.

PMID: 35126310 PMC: 8812007. DOI: 10.3389/fendo.2021.790169.

Meta-analysis of metabolic changes in children with idiopathic growth hormone deficiency after recombinant human growth hormone replacement therapy.

Yuan Y, Zhou B, Liu S, Wang Y, Wang K, Zhang Z Endocrine. 2020; 71(1):35-46.

PMID: 32740695 DOI: 10.1007/s12020-020-02435-w.

Glucose Metabolism in Children With Growth Hormone Deficiency.

Ciresi A, Giordano C Front Endocrinol (Lausanne). 2018; 9:321.

PMID: 29942285 PMC: 6005337. DOI: 10.3389/fendo.2018.00321.

References

Ciresi A, Ciccio F, Amato M, Giordano C . Revaluation of the clinical and metabolic behavior of children with isolated growth hormone deficiency during GH treatment according to newly proposed note 39 of the Italian Medicines Agency (AIFA). J Endocrinol Invest. 2015; 38(12):1301-7. DOI: 10.1007/s40618-015-0314-7. View

Hussain M, Schmitz O, Christiansen J, Zapf J, FROESCH E . Metabolic effects of insulin-like growth factor-I: a focus on insulin sensitivity. Metabolism. 1995; 44(10 Suppl 4):108-12. DOI: 10.1016/0026-0495(95)90230-9. View

CAVALLO , De Luca F , BERNASCONI , Arrigo , Gurrado , Zecchino . The effect of different growth hormone administration frequencies on growth in growth hormone-deficient patients . Horm Res. 1998; 49(# Suppl 2):73-7. View

Amato G, Mazziotti G, Di Somma C, Lalli E, de Felice G, Conte M . Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections. J Clin Endocrinol Metab. 2000; 85(10):3720-5. DOI: 10.1210/jcem.85.10.6881. View

Hindmarsh P, Stanhope R, Preece M, Brook C . Frequency of administration of growth hormone--an important factor in determining growth response to exogenous growth hormone. Horm Res. 1990; 33 Suppl 4:83-9. DOI: 10.1159/000181590. View

Capalbo D, Raso G, Esposito A, Di Mase R, Barbieri F, Meli R . Cluster of cardiometabolic risk factors in children with GH deficiency: a prospective, case-control study. Clin Endocrinol (Oxf). 2013; 80(6):856-62. DOI: 10.1111/cen.12393. View

Kastrup K, Christiansen J, Andersen J, Orskov H . Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh). 1983; 104(2):148-52. DOI: 10.1530/acta.0.1040148. View

Giovannini L, Tirabassi G, Muscogiuri G, Di Somma C, Colao A, Balercia G . Impact of adult growth hormone deficiency on metabolic profile and cardiovascular risk [Review]. Endocr J. 2015; 62(12):1037-48. DOI: 10.1507/endocrj.EJ15-0337. View

Ciresi A, Amato M, Criscimanna A, Mattina A, Vetro C, Galluzzo A . Metabolic parameters and adipokine profile during GH replacement therapy in children with GH deficiency. Eur J Endocrinol. 2007; 156(3):353-60. DOI: 10.1530/eje.1.02343. View

10.

Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412-9. DOI: 10.1007/BF00280883. View

11.

Grimberg A, DiVall S, Polychronakos C, Allen D, Cohen L, Quintos J . Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr. 2016; 86(6):361-397. DOI: 10.1159/000452150. View

12.

Utzschneider K, Prigeon R, Faulenbach M, Tong J, Carr D, Boyko E . Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care. 2008; 32(2):335-41. PMC: 2628704. DOI: 10.2337/dc08-1478. View

13.

Cutfield W, Derraik J, Gunn A, Reid K, Delany T, Robinson E . Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One. 2011; 6(1):e16223. PMC: 3031542. DOI: 10.1371/journal.pone.0016223. View

14.

Moore W, Nguyen H, Kletter G, Miller B, Rogers D, Ng D . A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency. J Clin Endocrinol Metab. 2015; 101(3):1091-7. PMC: 4803167. DOI: 10.1210/jc.2015-3279. View

15.

Ciresi A, Ciccio F, Radellini S, Giordano C . Utility of C-peptide for a reliable estimate of insulin secretion in children with growth hormone deficiency. Growth Horm IGF Res. 2016; 29:71-77. DOI: 10.1016/j.ghir.2016.05.001. View

16.

Moller N, Butler P, Antsiferov M, Alberti K . Effects of growth hormone on insulin sensitivity and forearm metabolism in normal man. Diabetologia. 1989; 32(2):105-10. DOI: 10.1007/BF00505182. View

17.

Ciresi A, Amato M, Giordano C . Reduction in insulin sensitivity and inadequate β-cell capacity to counteract the increase in insulin resistance in children with idiopathic growth hormone deficiency during 12 months of growth hormone treatment. J Endocrinol Invest. 2014; 38(3):351-9. DOI: 10.1007/s40618-014-0184-4. View

18.

. Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000; 85(11):3990-3. DOI: 10.1210/jcem.85.11.6984. View

19.

FRASIER S . Human pituitary growth hormone (hGH) therapy in growth hormone deficiency. Endocr Rev. 1983; 4(2):155-70. DOI: 10.1210/edrv-4-2-155. View

20.

Reginster J, Rabenda V, Neuprez A . Adherence, patient preference and dosing frequency: understanding the relationship. Bone. 2006; 38(4 Suppl 1):S2-6. DOI: 10.1016/j.bone.2006.01.150. View